☰

Braile Biomédica

Doubling capacity under three regulators at once

Industry
Medical Devices — Cardiac Surgery and Endovascular
Headquarters
São José do Rio Preto, São Paulo, Brazil
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Braile Biomédica's published strategy and is not endorsed by, or produced in cooperation with, Braile Biomédica. Company website

Strategic priorities

Braile Biomédica is committing R$ 27 million to double its factory footprint in São José do Rio Preto, with the investment directed at new machinery and infrastructure renovation. The expansion supports five business divisions — cardiovascular, biological, endovascular, electromechanical and oncology — and runs alongside a strategic licensing pact with Zydus MedTech to commercialise the TAVI (Transcatheter Aortic Valve Implantation) platform in India and Europe.

Regulatory positioning is the immediate pressure point: Braile was the first Brazilian company to obtain EU MDR (European Union Medical Device Regulation) certification, covering 1,175 product models, and now reports to ANVISA (the Brazilian regulator), CDSCO (India's Central Drugs Standard Control Organisation) and EMA (the European Medicines Agency) simultaneously. Devices are distributed in over 55 countries, with the 2022 revenue base of more than R$ 100 million and 55 percent year-on-year growth giving the capital needed to scale.

The R&D pipeline is unusually heavy for a mid-sized manufacturer: 11 ongoing clinical trials, 32 patents, and a vertically integrated value chain from raw bovine pericardium through to sterilised device. The doubling of factory size comes with 100 new positions, 70 percent of them on the production side, which puts training, inspection and data consistency on the critical path of the investment.

Challenges we see

  • Digital Integration

    Connecting new machinery to the existing ERP backbone

    The R$ 27 million expansion involves integrating new high-performance machinery with the existing infrastructure and the TOTVS Protheus ERP (Enterprise Resource Planning) system. The ERP records what was ordered; the shop floor has no shared view of how the order is being produced.

    Where production progress is reconstructed from paper or operator memory, the time between an issue and someone seeing it in the planning system is measured in steps rather than seconds, and those steps accumulate across the expanded factory.

  • Operations Manufacturing

    Standardising biological tissue inspection at higher volume

    Heart valve manufacturing uses bovine pericardium, a biological material with inherent lot-to-lot variability. Selection and treatment decisions are made by senior technicians whose criteria live in working experience rather than in a written specification.

    Where tissue acceptance depends on the expert eye of a small group, the doubling of throughput either absorbs that group's time or accepts a wider spread of accepted material, and the line has to be designed to make both outcomes visible.

  • Compliance Regulatory

    Reporting the same device data to three regulators

    EU MDR certification covers 1,175 product models. The Zydus partnership adds reporting to CDSCO in India, and the home market is ANVISA. Periodic Safety Update Reports (PSURs) and technovigilance data are aggregated across 200-plus institutions in 55 countries.

    Where each jurisdiction asks for the same underlying device performance data in a different shape, the cost of reporting scales with the number of jurisdictions rather than with the number of devices, and the data layer has to absorb that.

  • Digital Operations

    Holding R&D data together across 11 trials and 32 patents

    The PD&I unit runs 11 ongoing clinical trials and holds 32 patents. Research records are stored across spreadsheets, paper logs and lab instruments, with no shared search across studies or experiments.

    Where each study is its own data island, the time to assemble evidence for a patent filing, a regulatory submission or a follow-on experiment grows with the number of studies, and the PD&I team carries the cost of that growth.

  • Operations Manufacturing

    Onboarding 100 new production staff without losing process consistency

    The expansion plan adds 100 positions, 70 percent of them in production. New operators are trained alongside experienced technicians, and there are no digital work instructions or augmented-reality guidance to make procedure execution repeatable across the shift.

    Where the same procedure is performed by different people on different shifts, the difference between a passing and a failing result is held in the variation between operators, and the standard of work needs to be carried by the work instructions rather than by the people.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Closing the gap between shop-floor data and TOTVS Protheus

    TOTVS Protheus is an accounting-first ERP, and the new machinery is not connected to it. Production progress, batch state and machine status live separately from the order book, so the management view of the factory is reconstructed rather than observed.

    An IT/OT (Information Technology / Operational Technology) integration layer can stream machine and operator events into the ERP, turning the factory floor into a system of record the planning team can read directly. The result is a live picture of the expanded plant instead of a daily roll-up of what already happened.

    • Braile Biomédica R$ 27 million investment announcement, 2023
    • Braile case study on IT/OT convergence with TOTVS Protheus

  2. Making tissue selection reproducible across the shift

    Bovine pericardium selection is a per-lot judgement made by senior technicians. At twice the throughput the same judgement has to be made by more people on more shifts, and the criteria that distinguish an acceptable lot from a rejected one are not written down anywhere a machine can read them.

    Camera systems with image-classification models trained on expert-graded tissue lots can apply the same criteria every time, and a digital twin of the glutaraldehyde fixation process can predict treatment outcomes from tissue characteristics before the lot goes into the bath.

    • Braile Biomédica divisions and product portfolio
    • A4BEE case study on AI-driven tissue selection

  3. Generating one regulatory submission per jurisdiction from shared data

    PSURs and technovigilance reports cover 200-plus institutions in 55 countries. The same underlying device performance data is currently re-keyed into the format each regulator asks for, so the time to compile a submission scales with the number of jurisdictions rather than the number of devices.

    A regulatory data model that holds device performance, complaint, field action and clinical follow-up data once and renders it into ANVISA, CDSCO and EMA submissions in parallel can replace the per-jurisdiction compilation with a shared evidence base and a configurable rendering step.

    • Braile Biomédica first Brazilian MDR certification, 2018
    • EU MDR Periodic Safety Update Report guidance

  4. Unifying R&D data across clinical trials and patents

    11 ongoing clinical trials and 32 patents generate data across PD&I workstations, lab instruments, partner sites and external CROs (Contract Research Organisations). Records are kept in spreadsheets, ELNs (Electronic Laboratory Notebooks) from different vendors and paper logs, and assembling evidence for a patent filing or regulatory submission is a manual search.

    An ELN-plus-LIMS (Laboratory Information Management System) backbone with a shared ontology for experiment, sample, result and patent can make each study searchable across the PD&I portfolio, so the time to assemble evidence drops with the number of records rather than growing with it.

    • Braile Biomédica R&D and clinical pipeline overview
    • A4BEE case study on ELN-LIMS integration

  5. Designing the technology transfer layer for the Zydus partnership

    The Zydus partnership requires the TAVI manufacturing recipe to move from São José do Rio Preto to India and Europe. The recipe currently sits in operator knowledge, paper batch records and instrument setpoints, and any error in transfer has to be detected after the receiving site has produced a non-conforming batch.

    A process digital twin that holds the equipment configuration, parameter ranges, in-process checks and quality gates for the TAVI line can act as the single source of truth for the receiving site, with role-based access and audit trails that protect the underlying IP during transfer.

    • Braile-Zydus TAVI licensing announcement, 2024
    • A4BEE case study on pharmaceutical technology transfer

What we'd propose

  • Digital CDMO

    IT/OT integration layer for the expanded São José do Rio Preto plant

    An integration layer that connects new and existing machinery to TOTVS Protheus through a documented OPC UA (Open Platform Communications Unified Architecture) and MQTT (a lightweight messaging protocol widely used in industrial IoT) data path, so production events, batch state and machine status arrive in the ERP as structured records rather than reconstructed summaries.

    • Machine and instrument data acquisition

      Getting events off the line

      Connect controllers, sensors and inspection stations through OPC UA or MQTT so production events leave the equipment in a documented, vendor-neutral form rather than staying inside a closed controller.

    • Live production state in the ERP

      ERP that knows what is on the line

      Stream batch progress, operator and resource state into TOTVS Protheus so the planning team reads the factory directly, with batch genealogy (the complete record of where each unit, material and process step came from) maintained end-to-end for cardiac implant traceability.

    • Alerting against the running batch

      Issues raised while work continues

      Build the normal operating envelope for each critical process parameter from historical runs and flag drift against the current batch, so a deviation surfaces while the unit is still on the line rather than after it has been released.

    • Production state is read directly from the line rather than reconstructed each morning.
    • One set of production data serves planning, quality and engineering instead of three separate extracts.
    • Bottlenecks are visible while the shift is still running rather than after the day is closed.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Computer vision and digital twin for biological tissue quality

    A camera-based inspection system for bovine pericardium lots, paired with a digital twin of the glutaraldehyde fixation process, so the criteria that currently live in the senior technicians' judgement are applied consistently by an automated grading step.

    • Computer vision tissue grading

      Consistent lot acceptance

      Deploy camera systems with image-classification models trained on expert-graded tissue lots, so the same selection criteria are applied to every lot regardless of which technician is on shift.

    • Digital twin of chemical fixation

      Treatment predicted before the bath

      Build a simulation of the glutaraldehyde fixation process that predicts treatment outcomes from tissue characteristics and process setpoints, supporting the choice of cycle parameters per lot.

    • Knowledge capture for the expert criteria

      Tacit criteria made explicit

      Document and digitise the decision criteria used by senior technicians into the training dataset for the vision model, so institutional knowledge is preserved as the workforce expands.

    • Tissue acceptance criteria are applied consistently across shifts and sites.
    • Fixation parameters are chosen per lot from simulation rather than from a fixed recipe.
    • Expert judgement is preserved as the production workforce doubles.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Multi-jurisdiction regulatory data platform

    A regulatory data platform that holds device performance, complaint, field action and clinical follow-up data once, then renders PSURs and technovigilance submissions in the format each regulator asks for, so the same evidence base serves ANVISA, CDSCO and EMA in parallel.

    • Shared regulatory data model

      One record per device event

      Define device, lot, complaint, adverse event and clinical follow-up as explicit entities with agreed relationships, so a single record can be queried across ANVISA, CDSCO and EMA submissions rather than re-keyed per jurisdiction.

    • Submission rendering per jurisdiction

      One evidence base, three outputs

      Build the rendering logic that turns the shared record set into the periodic report template each regulator expects, with jurisdiction-specific deadline tracking built into the workflow.

    • Technovigilance signal detection

      Adverse events flagged early

      Run statistical and rule-based checks over complaint and field action data so that an emerging safety signal surfaces in the regulatory team's queue before it would have done from manual review.

    • Reporting effort scales with the number of devices rather than the number of jurisdictions.
    • The same evidence base supports MDR, ANVISA and CDSCO submissions in parallel.
    • Emerging safety signals are visible to the regulatory team earlier in the cycle.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Unified R&D data layer for the PD&I unit

    An ELN-plus-LIMS backbone for the PD&I unit, with a shared ontology for experiment, sample, result and patent, so the 11 clinical trials and 32 patents are searchable across the PD&I portfolio and the time to assemble evidence for a regulatory submission drops with the size of the portfolio.

    • Electronic lab notebooks for PD&I

      Records captured at the bench

      Replace paper and spreadsheet research logs with structured ELN templates that capture experiment, sample, instrument and result together, with versioning and search built in.

    • Clinical trial data integration

      Trials visible across the portfolio

      Connect clinical trial data streams from partner sites and CROs into a unified analytics view, so each trial can be compared against the others and the portfolio's evidence base is readable in one place.

    • Patent pipeline view

      Innovation progress in one chart

      Build a portfolio dashboard that tracks each patent and research project against its milestones and resource allocation, giving the PD&I leadership a single view of where the pipeline stands.

    • Each study is searchable across the PD&I portfolio rather than held in its own spreadsheet.
    • Evidence for a patent filing or regulatory submission is assembled from search rather than from recollection.
    • Clinical trial data from partner sites flows into the same view as in-house studies.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Process digital twin for the TAVI technology transfer to Zydus

    A process digital twin for the TAVI manufacturing line that holds the equipment configuration, parameter ranges, in-process checks and quality gates, with role-based access for the receiving site and audit trails that protect the underlying IP during transfer.

    • TAVI process digital twin

      Single source of truth for the line

      Build a digital model of the TAVI production process that captures equipment configuration, parameter ranges, in-process checks and quality gates in a form the receiving site can read against its own equipment.

    • Role-based knowledge repository

      IP protected during transfer

      Establish an encrypted document and data repository with role-based access control, versioning and audit trails, so the process knowledge shared with Zydus is the minimum needed for each role and the rest stays inside Braile.

    • Remote collaboration on commissioning

      On-site support from São José do Rio Preto

      Deploy screen sharing, video walk-throughs and AR-assisted remote guidance so that the São José do Rio Preto team can support the Zydus commissioning in real time without travelling for every step.

    • TAVI transfer happens against a documented process rather than against operator memory.
    • Shared knowledge is the minimum each role needs, with the rest held inside Braile.
    • Commissioning issues are resolved in real time across the two sites.

    We've done this before

    See how we do Enterprise AI

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Braile Biomédica's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
IT/OT integration 30 → 80
TOTVS Protheus is the system of record for orders, and the shop floor is not yet connected to it. The expansion is bringing in new machinery, so the IT/OT layer is being designed at the same time as the new lines.
Data analytics 25 → 75
Research data lives in spreadsheets and paper logs, production data lives next to the machines and the ERP holds the order book. The analytics question is therefore largely one of joining these three sources together.
Process automation 35 → 85
Tissue inspection is a per-lot judgement made by senior technicians, and 70 percent of the 100 new positions will sit on the production side. The standard of work needs to be carried by the work instructions rather than by the people.
Regulatory compliance systems 45 → 90
Braile was the first Brazilian company to obtain EU MDR certification, so the regulatory posture is already strong; the question now is whether ANVISA and CDSCO submissions can be produced from the same evidence base as the MDR file.
Cloud infrastructure 20 → 70
Most systems run on premise, and the Zydus partnership requires cloud-based data sharing with partners in India and Europe. The cloud strategy is therefore being shaped by the partnership requirement as much as by internal preference.
Workforce enablement 25 → 70
The 100 new positions, with 70 percent in production, create a training and competency challenge that is larger than the current digital work-instruction footprint can absorb. The expansion is the trigger for building that layer.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Braile Biomédica, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].